

RESEARCH ARTICLE

Open Access

# The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter

Jennifer L Barton<sup>1,2\*</sup>, Christopher J Koenig<sup>1</sup>, Gina Evans-Young<sup>1,3</sup>, Laura Trupin<sup>1,3</sup>, Jennie Anderson<sup>4</sup>, Dana Ragouzeos<sup>4</sup>, Maggie Breslin<sup>5</sup>, Timothy Morse<sup>4</sup>, Dean Schillinger<sup>1</sup>, Victor M Montori<sup>6</sup> and Edward H Yelin<sup>1,3</sup>

## Abstract

**Background:** Shared decision-making in rheumatoid arthritis (RA) care is a priority among policy makers, clinicians and patients both nationally and internationally. Demands on patients to have basic knowledge of RA, treatment options, and details of risk and benefit when making medication decisions with clinicians can be overwhelming, especially for those with limited literacy or limited English language proficiency. The objective of this study is to describe the development of a medication choice decision aid for patients with rheumatoid arthritis (RA) in three languages using low literacy principles.

**Methods:** Based on the development of a diabetes decision aid, the RA decision aid (RA Choice) was developed through a collaborative process involving patients, clinicians, designers, decision-aid and health literacy experts. A combination of evidence synthesis and direct observation of clinician-patient interactions generated content and guided an iterative process of prototype development.

**Results:** Three iterations of RA Choice were developed and field-tested before completion. The final tool organized data using icons and plain language for 12 RA medications across 5 issues: frequency of administration, time to onset, cost, side effects, and special considerations. The tool successfully created a conversation between clinician and patient, and garnered high acceptability from clinicians.

**Conclusions:** The process of collaboratively developing an RA decision aid designed to promote shared decision making resulted in a graphically-enhanced, low literacy tool. The use of RA Choice in the clinical encounter has the potential to enhance communication for RA patients, including those with limited health literacy and limited English language proficiency.

**Keywords:** Decision aid, Rheumatoid arthritis, Health literacy

## Background

Significant advances have been made in treatment options and strategies for rheumatoid arthritis (RA), one of the most common forms of inflammatory arthritis. These advances have shifted the goal of therapy from symptom relief to sustained remission. Over the past twenty

years, 10 new disease-modifying anti-rheumatic drugs (DMARDs) have been approved by the FDA for use in RA. These innovations have improved outcomes, but introduced high complexity for patients and clinicians when making treatment decisions about individual agents and their use in combination. Like the treatment of many other chronic diseases, adherence to biologic DMARDs can be poor with persistence rates ranging from 42-71% [1].

Despite advances in therapy, variation in outcomes persists, with certain populations experiencing poorer

\* Correspondence: Jennifer.Barton@va.gov

<sup>1</sup>Department of Medicine, University of California, San Francisco, CA, USA

<sup>2</sup>Division of Hospital & Specialty Medicine, Portland Veterans Affairs Medical Center, 3710 SW US Veterans Hospital Road, Portland, OR 97239, USA

Full list of author information is available at the end of the article

outcomes [2,3]. In particular, RA patients who are non-white, immigrants, or who have limited English language proficiency have been found to have higher disease activity and poorer function despite access to effective therapies [4]. In addition, limited health literacy has also been associated with greater disability [5]. We define health literacy using the Affordable Care Act of 2010 definition: “the degree to which an individual has the capacity to obtain, communicate, process, and understand basic health information and services to make appropriate health decisions”. One potential mechanism for persistent variation in outcomes is variation in the interpersonal processes of care, such as patient-provider communication. We have found that nearly one-third of adults with RA report suboptimal shared decision-making (SDM) communication. Patients with lower education, limited health literacy, lower trust in physician and limited English language proficiency are more likely to report suboptimal SDM [6].

Shared decision-making in RA care is a priority among policy makers, clinicians and patients both nationally and internationally [7-10]. The demands on patients to have a basic level of knowledge of RA, the therapeutic options, and details of safety and efficacy of treatments when making a decision with their clinicians can be overwhelming, especially for those with barriers to communication like literacy or language. Competing tasks place clinicians at a disadvantage as they may not find time to inform patients of treatment options, discuss benefits and harms, and engage patients in shared decision-making.

Taking into account these increasing demands on patients and clinicians, evidence of suboptimal SDM, and disparities in outcomes, we set out to design a decision aid for use in the clinical encounter to facilitate conversation between patients and clinicians around issues related to RA medications. Here we describe and discuss lessons learned in the development of the decision aid.

We based the RA decision aid development on a process used to design a tool for patients with diabetes [11] which has been shown to enhance knowledge and improve patient involvement in decisions [12]. Breslin et al. noted that the shared decision-making model for patients with chronic disease must begin with partnership building, sharing of information, shared deliberation and, ultimately, joint decision making. They observed that patients make decisions about medications *after* leaving the clinician’s office, without the opportunity to ask questions, state their preferences or air concerns about medications. The motivation behind the diabetes decision aid design was to encourage patients to share concerns, raise issues, and ask questions *during the encounter* such that patient and clinician could arrive at a decision together. In this manner, clinicians could gain

a shared understanding of the patient’s preferences, values, and context, and patients could make decisions about starting and using medicines informed by the clinician’s experience and expertise. Therefore, the goal of this project was to use a collaborative user-centered design process to create a tool, the RA decision aid, to facilitate patient engagement when choosing a new DMARD. Given the disparities in RA outcomes [2-4] and reports of poor shared decision-making communication among vulnerable populations, we chose to develop our tools for those with limited health literacy and include non-English languages of Spanish and Chinese. The concept of health literacy was addressed in the RA decision aid by following guidelines for developing low literacy materials (e.g., use of icons, plain language, more white space) as well as including patients of all literacy levels in the development process, and creating a tool that focused less on reading and more on conversation and verbal exchange of information. We adopted a collaborative approach, sometimes referred as participatory action research [13], to develop the decision aid. This process involves patients and clinicians – the users – at every step of the process, as well as experts in the development of decision aids, health literacy, and designers to translate the materials into a tool that users would want to use.

## Methods


### Overview

Given that the majority of patients newly diagnosed with RA are started on methotrexate [14,15], we created our tool for the clinical context of an established RA patient with moderate to high disease activity who, at a minimum, has failed a trial of methotrexate. A 2013 study reported on the non-inferiority of triple combination synthetic DMARD therapy compared to adding a biologic [15] to methotrexate such that there is no one algorithm to direct medication choice in RA. At the time of the decision aid development, twelve DMARDs (4 synthetic and 8 biologic DMARDs) had been approved by the FDA and were commonly used in practice. While there are more than 12 FDA-approved DMARDs for RA, several are very rarely used in clinical practice.

The research protocol for this study was approved by the UCSF Committee on Human Research (IRB Number: 10-02339). All patient participants gave their written informed consent to be part of the study. All individuals whose images appear in the guide (Figure 1) signed written consent for permission to use their images for the purposes of the guide (research and education).

### The team

Using the design of the diabetes issue cards as a guide, we convened a diverse group of individuals with expertise in



Chapter 1

## What is rheumatoid arthritis (RA)?

**What is RA?**  
When you have rheumatoid arthritis, your immune system, which usually fights infection, attacks the lining of your joints and causes inflammation. Inflamed joints can be swollen, stiff, and painful. The small joints of your hands and feet are usually affected first.



Once you have RA, it never goes away. You have it for life. Medicines can help with pain and stiffness in your joints and prevent permanent damage to your joints.

**How do you get RA?**  
No one knows exactly what causes RA. It is most likely a combination of your genes and the environment. Smoking also increases your chances of getting RA.



**What can RA do to your body?**

- Cause swelling, warmth and pain in your joints
- Permanently damage your joints
- Cause inflammation of your eyes, blood vessels, or lungs
- Weaken bones (osteoporosis)
- Cause anemia (low blood cell counts)
- Make you feel very tired
- Give you a fever
- Cause changes in your weight
- Make you feel sad or depressed



**Who gets RA?**

- Anyone can get RA.
- You can get it at any age.
- Women are 2-3 times more likely than men to get RA.

**Is there a cure for RA?**  
No medicine can cure RA, but medicine can slow down damage to joints and ease pain. Most people have to take pills, shots, or medicine by vein (IV or intravenously).

**When should you begin to take medicine for RA?**

- It is important to take medicine for RA as soon as a doctor tells you that you have it.
- People who take medicine early are able to do everyday activities better and are less likely to have permanent damage to their joints than those who wait.

**Do people with RA have other health problems?**  
Yes, some do. You may have a greater risk of:

- Heart disease
- Certain types of cancer (lymphoma – a blood cancer)
- Broken bones from osteoporosis

**“I even flew back to China to try to get a cure for it because... I thought there *was* a cure.”**  
- Joan, age 25




Chapter 1  
What is rheumatoid arthritis (RA)?

4 | 5

Figure 1 Cover of the patient education material, “your guide to rheumatoid arthritis medications”, and two-page spread of chapter 1: “What is rheumatoid arthritis?”.

RA (clinicians and patients), decision aid research (VMM), design (TM, MB, DR), health literacy (JA, DS), clinical and qualitative research methods (LT, EY, CJK). We adopted the design approach described by Breslin et al. and encouraged all members of the team to bring methodologies and ideas from their respective fields to the table. This approach, with foundations in the design discipline, draws upon elements of field ethnography (which involves direct observation in clinic about how patients and clinicians discuss treatments) as well as participatory action research where both patients and clinicians contribute to the research by allowing participant observers (or third party researchers) to observe actual clinic visits. In addition, patients contributed by informing the researchers about content of the decision aid and evaluating prototypes both on an individual basis in cognitive interviews and as a larger group in a patient advisory board. Results from the cognitive interviews fed back directly into decisions regarding design, number of issue cards, and as a factor in how many cards were ultimately included in the final deck. Content from the interviews was discussed in team meetings and phone calls with consultants and designers.

Patients participated in two ways. The first was to invite patients from several previously conducted focus groups (one each in English, Spanish or Cantonese led by a bilingual, trained focus group moderator using a common interview guide that had been translated) to sit on a patient advisory board which met approximately every two months during the 18-month-long development process. The purpose of the initial focus groups was to gather data to inform the content and delivery of an adapted medication summary guide for RA medications as well as to explore patients' perspectives on participation in decision making with their clinicians. The Grounded Theory Method [16] using constant comparison to determine similarity and differences within and between groups was used to analyze the transcripts [17]. We recruited heavily from the county hospital clinic for the focus groups, of whom over half had high school education or less. We then selected members for the board who had a range of literacy and education levels and continually emphasized the low literacy principles for the tool development. Of 9 board members, one-third had limited health literacy. The common language was English; however, several members were bilingual (either in Spanish or Cantonese). Cantonese, not Mandarin, is the predominant language spoken by Chinese speakers in San Francisco. Patients also participated during clinic visits at one of two clinics, the university-hospital based arthritis clinic or the county-hospital based RA clinic, when the prototypes were being tested. Clinical rheumatologists provided input as they tested the prototypes in clinic and offered feedback in research meetings.

### The development process

In addition to using the diabetes issue cards as a template, we followed six steps for the development of low literacy materials outlined by Seligman et al. [18] where the authors describe a process whose main purpose is to create materials which will increase knowledge as well as activate low literacy patients toward healthier behaviors. The six steps are presented in Table 1. Seligman et al. underscore the importance of mapping concepts onto a behavioral theory, such as the social cognitive theory, which suggests that materials should improve knowledge, positively influence outcome expectations, emphasize facilitators of behavior change, address barriers to behavior change, and facilitate the creation of goals [19].

The funder of this project, the Agency for Healthcare Research and Quality (AHRQ), published a summary of their comparative effectiveness review of RA medications for patients and clinicians [20,21]. Results from this review were used as the basis of the literature review for the decision aid. Additional systematic reviews of DMARDs and classes of DMARDs [22-25] were used to supplement the AHRQ review. In addition to gathering evidence-based reviews on DMARD safety, tolerability and comparative effectiveness, we also collected data on how medication discussions were taking place in clinics, as well as eliciting patient concerns about starting a new medication in focus groups, cognitive interviews, and from the advisory board. The process of combining data from the evidence synthesis and direct observations with feedback from various stakeholders is illustrated in Figure 2.

The development team reviewed and discussed issues that emerged from the literature review, clinical observations, and patient comments, and began to create prototypes of the cards. Each card was devoted to a particular issue, such as "side effects" or "cost" as based on the diabetes card design. The number, content, and design of the cards varied throughout their development. Clinicians were asked to use prototypes in clinical encounters where a third party (GEY) observed and recorded how the tool was used, the content of conversations around medications, and the level of patient involvement in the encounter. Prototypes were evaluated in recorded one-on-one interviews with a member of the research staff (LT, JB) and RA patients, as well as non-RA patients (in role play) to gather insights into the content and design of the tool and its ability to generate a conversation. Mock clinic visits and actual clinic visits using the prototypes were then observed by the designer (TM) and other team members (LT, GEY) after which they provided feedback on the nature of the conversations. Health literacy experts also reviewed the prototypes.

In discussions with the patient advisory board, we sought to identify any issues that the cards did not cover

**Table 1 Six steps for developing low literacy educational materials**

Key concept	Study phase
1. Convene a working team and solicit stakeholder input early	Phase 1 – Focus groups English-speaking RA patients Spanish-speaking RA patients Cantonese-speaking RA patients Rheumatologists
2. Identify key concepts to be communicated	Focus groups provide feedback on main areas of content: • Broad category of medicines for RA • Benefits of DMARDs across mono- and combination therapies • Talking with the doctor about RA drugs • Learning about risks • Ways to reduce risk • Cost
3. Map concepts to a behavioral theory, such as social cognitive theory and construct a brief intervention to support the use of written materials	Phase 1 -social cognitive theory suggests that materials should: • improve knowledge • positively influence outcome expectations • emphasize facilitators of behavior change • address impediments to behavior change • facilitate the creation of goals
4. Carefully design materials using low-literacy principles	Phase 2: adopt AHRQ summary guide for low literate, limited English language proficient patients • Use illustrations • ≥ 14 pt font • Adequate white space
5. Refine materials using input from the target population	Phase 2 • In-depth, semi-structured interviews • Review adapted guides with patient advisory board
6. Assess success of efforts in target audience and learn from failures	Phase 3 – pilot test of decision aid, evaluate acceptability and outcomes of knowledge and decisional conflict

and therefore expand the repertoire of issues. Most importantly, we examined whether the cards accomplished the goal of creating a conversation between patient and clinician. Iterations of the tool continued until the main patient issues and concerns were covered

and the cards were consistently generating an exchange between clinician and patient about RA medications. This entire process took approximately eighteen months.

**Role of the funding source**


AHRQ funded this project and played no other role in this work.

**Results**

**Developing the decision aid**

**Content**

The content was derived from the AHRQ and other evidence-based reviews as depicted in Figure 2. The DMARDs presented in the original AHRQ summary guide included anakinra which upon discussions with local rheumatologists was deemed to be used exceedingly rarely in the treatment of adult RA. Therefore, anakinra was not included. A total of twelve DMARDs were included: synthetic DMARDs - hydroxychloroquine, leflunomide,



methotrexate, sulfasalazine; biologic DMARDs - abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab, tocilizumab. The newest FDA-approved DMARD for RA, tofacitinib [27], received its approval after development was completed and is not included.

Route of administration, frequency of dosing, and side effects vary among DMARDs and play a role in patient preferences for choosing an RA medication [28-33]. Other important patient issues that emerged in focus groups, advisory board meetings and in clinical encounters included cost, benefits, and time until clinical effects are experienced. Clinician concerns included special considerations such as pregnancy (some DMARDs are teratogenic), latent or active tuberculosis (all biologic therapies increase the risk for opportunistic infections including TB), and alcohol consumption (methotrexate and leflunomide can be hepatotoxic; heavy alcohol consumption is contraindicated). Clinicians aware of the benefits of combination therapy using two or more DMARDs to achieve greater efficacy were interested in a combination DMARD issue card as well as one which would address goals of therapy for RA.

#### **Form and information design**

The team decided *a priori* to use the issue card format developed by Breslin and colleagues at the Mayo Clinic. Therefore, our prototypes varied over time in the number of issue cards in each “deck”, and the design and content of each card. At three distinct time-points we had a collection of cards which varied by number and appearance, as discussed below.

#### **First prototype deck**

Our initial set of cards consisted of six issues: medication routine, cost, results (time to onset), side effects, infection risks, and special considerations. Ten medications (methotrexate and rituximab were not initially included) were organized with pills on one card and then IV/subcutaneous injectables on another. We then combined all medications onto one card in a consistent way across all issues grouping them by mode of administration: oral, subcutaneous (“shots under the skin”) and intravenous delivery (“given in the vein”). Following low literacy principles to use more illustrations, the research team explored the use of images: photographs of pills, a person giving himself an injection, and an arm with an IV as well as cartoons or icons.

We elicited feedback from a group of rheumatologists and from the patient advisory board on this first iteration. Physicians overall were concerned that the cards “may open a can of worms” and prolong the length of the clinical encounter, however they felt certain cards (like the “routine” card) were very important. Specific


clinician feedback included suggestions to add icons for pills/IV/subcutaneous injections; separate common from rare and mild from severe side effects; and add a “benefits” card to show efficacy. Clinicians emphasized that they often have their own order in which they present medication options (e.g., 1<sup>st</sup> line, second line, third, etc.) and were concerned that patients may interpret the order in which the medications are listed on the cards as an order of preference. Physicians felt that the cost issue was very individualized depending on patient insurance and that it may be more important to first make the decision regarding which medication and *then* deal with cost. Also, they were concerned that patients may perceive this card in a negative way, as in: “why should we care about costs?” Clinician concerns around cost were misaligned with those of patients who expressed interest and concern about medication cost in focus groups and during prototype reviews. One Cantonese-speaking patient upon seeing the actual costs of a biologic commented: “If you want me to pay, I prefer to die. Where can I get the money?”

Patient advisory board members piloted the cards using role play with one another and two researchers (GEY, LT). During this exercise, several patients took on the role of a patient and the other a doctor while a third party observed the conversation. Elicitation of values and concerns were observed during the use of the cards, cost was discussed frequently as was mode of administration and onset of action. No issue cards were felt to be missing from the discussion though one patient wanted to see prednisone (which is not traditionally considered a DMARD) on the cards.

The designers then piloted three different visual designs (Figure 3).

#### **Second prototype – deck #2**

The research team and designers, with feedback from the patient advisory board, selected their preferred font, colors, icons, and layout for a consistent visual presentation in this next iteration (Figure 4). In addition to the design revision, a “benefits” or efficacy card was added in response to feedback, and infection risk was incorporated into the side effects card. For the benefits card, the research team chose to use pictographs to illustrate efficacy given a growing body of evidence showing that pictographs are more quickly and better understood than other graphical formats [34]. The benefits card illustrated the number of people out of 100 who achieve an American College of Rheumatology (ACR) 50 response which reflects a 50% improvement in tender and swollen joints and 3 of 5 additional criteria [35] to each of the listed medications. This is a standard measure of efficacy included in RA clinical trials and data for this domain was extracted from the literature review.




**Figure 3** First iteration of the issue cards. Note the variation in the size of text, fonts, use of icons, and organization of medication names. Six issue cards were included in this “deck”: routine, cost (as seen above), results (onset of action), side effects, infection risk and special issues. (A) Design 1, (B) Design 2, (C) Design 3.

Ongoing clinician feedback led to prototypes of three additional cards: mode of administration, combination therapy, and goals. The “mode” card (Figure 5a) illustrated route of administration using icons of a pill, a pre-filled syringe and an infusion bag with tubing and needle as well as icons of a home and clinic/hospital to depict the setting. The combination therapy card (Figure 5b) came out of discussions with clinicians who are aware of the evidence that combination therapy of a synthetic DMARD such as methotrexate with a biologic has superior efficacy than monotherapy with either agent [36]. This is also true of combination therapy with synthetic DMARDs (e.g., triple therapy with methotrexate, hydroxychloroquine and sulfasalazine) [37]. Clinicians and the research team also felt that prior to initiating a discussion of the issue cards with a patient, clinician and patient goals for therapy be established. Goal concordance between patient and provider has been shown to lead to better outcomes in other chronic diseases [38,39]. This prompted the prototype of a “goals” card (Figure 5c).

**Final decision aid tool – deck #3**


Several changes were made to this final deck in response to feedback from multiple stakeholders. Clinicians were

extremely concerned about the amount of time it would take to review all eight issue cards (including the goals and combination therapy card) however they did note that the cards pushed them to consider patient preference as well as their own which they acknowledged promoted patient-centered care (their default was to tell the patient which drug they preferred, as opposed to eliciting patient preferences; the cards helped initiate that conversation). Patients reported some difficulty reading lighter color text on top of color, but liked the icons and calendar depictions. In cognitive interviews, it became clear that the goals card generated tangential conversations which distracted patients and providers from the task at hand. The combination card did not add to the conversations and it was deemed by our decision aid expert to be a “doctor” card in that it was information the doctor could easily convey in a sentence and was not an issue of importance to the patient. With respect to time, visits during the initial prototype testing varied from 30 to 60 minutes. We attributed some of this to a lengthy introduction of the tool to patients as well as a greater number of issue cards in the deck (Deck #2 - 8 cards). Three cards were then eliminated from the deck (goals, benefits, combination therapy) and a more stream-lined



**Figure 4** Second iteration of issue cards. This deck included one new issue card on benefits, and collapsed the infection risk card into the side effect card for a total of six cards: (A) benefits, (B) considerations (special issues), (C) cost, (D) results, (E) routine, (F) side effects.





approach to using the cards in the clinic was developed. With these adjustments, visit length on average was 33 - minutes (range 12-57 minutes) and often did not take longer than a visit without the tool. One user reported an increase visit time of 2 minutes with the tool. Clinicians were asked to start the conversation about choosing a medication with three main issue cards (how often, how soon and cost), and if patients asked questions about side effects or raised concerns related to special considerations, those cards would be pulled into the conversation. Thus the team arrived at a final set of five issue cards to be used in the clinical encounter (Figure 6). The final tool was translated and back-translated [40] into Spanish and Chinese by a professional translation agency (Figure 7).

## Discussion and conclusion

### Discussion

The development of a low literacy medication decision aid (RA Choice) in three languages was feasible using a collaborative process with patient and clinician input at every step. There is a clear need for increased support and structure to promote and facilitate shared decision-making in RA, especially among more vulnerable populations with poorer health outcomes and barriers to communication like literacy and language. Decision aids

are one way to promote patient-centered care [41]. There are several decision aids for patients with RA [42-44], however none have been developed for patients with limited health literacy or limited English language proficiency for use in the clinic encounter.

During our development process, certain decisions had to be made to respect clinician concerns about consultation time, inability to have comprehensive information on the cards and meet standards for a low literacy tool, and be cognizant of not overwhelming patients with too much information. We based our tool development on a process described for a diabetes decision aid, the overarching goal of which was to create a conversation between patients and clinicians. Both diabetes and RA are chronic conditions with multiple options for therapy requiring a high degree of self-management. Given the parallels between the two conditions and choices for therapy, the diabetes issue card design was an excellent template for the RA decision aid.

Our process was not without limitations. While we created the decision aid and translated (and back-translated) it into Spanish and Chinese, we found it difficult to fully involve Cantonese-speaking patients and research staff in the process. Due to time constraints we were unable to thoroughly pilot the tools with Cantonese




Figure 6 Final set of five issue cards and a cover page (F) for a tri-fold copy of the cards given to patients at the end of their clinic visit. (A) Considerations, (B) Cost, (C), How Soon?, (D) How Often?, (E) cover page, (F) Side Effects.




Figure 7 Illustration of the special considerations issue card in each of the three languages: (A) English, (B) Spanish and (C) Chinese.

speakers, interpreters, and clinicians in the clinics. There are both language and cultural adaptations which may enhance the use and efficacy of RA Choice given the opportunity to observe a broader number of encounters and this is a goal for future projects. More specifically, lessons learned for future work include a focus on a single language during development, more in depth cognitive interviews with Cantonese speakers, and to determine the best way, without using names or characters, to share information on medications (of note, only one of 7 Cantonese focus group participants could recognize the written name of their RA medications and relied on color and size of pill). In addition, background research on shared decision making preferences in these populations is needed. We chose to create a print tool (as opposed to web-based) which may limit its usability in clinics which are fully electronic, as well as limit, if effective, our ability to distribute it and keep it up-to-date without having to recall distributed cards. It may also make it more difficult to keep the tool updated with new medications or comparative effectiveness data. A web-based version of the tool may be more appropriate once exam rooms are better equipped for full participation of patients and providers and the investment justified by evidence of efficacy of the cards. It is also a challenge to create a design that appeals to all users, therefore an electronic tool tailored to each

individual may have greater reach as well as be easier to update. The state of the comparative effectiveness literature made it impossible to accurately depict benefits (lack of head to head trials for all biologics) and the research team ultimately concluded that using a measure such as the ACR 50 misled patients (i.e., depicting one medicine as more effective, leading to more patients achieving an ACR 50, when head-to-head trials are either not available or suggest no difference). This led to a decision not to include an issue card on efficacy. The complete experience of the decision aid tool in the clinical encounter relies on the communication skills of the clinician to engage the patient in conversation and of the patient to engage in conversation and for both to use the tools as intended. In contrast to the development of the diabetes decision aid, we were not able to pilot test the cards in actual clinical encounters in high numbers consistently across the tool development (more so in the beginning stages) due to the fact that clinics would be sites for a pilot trial.

The tool, in and of itself, does not meet all International Patient Decision Aid Standards (IPDAS) Collaboration criteria, which were designed for standalone tools directed at patients. However, cumulative, including through this publication, the tool satisfies criteria for balanced evidence-based and up-to-date information, depiction of relevant issues using state-of-the-art approaches, and

designed for purpose and setting [45]. The categories of the IPDAS criteria that were not met include: a description of the positive features (as discussed above a benefits issue card is not included in the deck), presentation of probabilities of outcomes (to do so would have added significant complexity to the design of the tool which in turn would create excess burden on patients with limited health literacy). In terms of values clarification, this takes place upon the introduction of the issue cards by the clinician when he or she asks the patient to “pick which issue you would like to discuss first” about a new medication. The act of allowing the patient to hold and select an issue card is a concrete way to allow the patient to clarify and express his or her values. By providing a copy of the decision aid in the form of a trifold pamphlet as well as the medication summary guide to take home, patients are also encouraged to share with family or friends what may matter most to them in choosing a medication – be it cost, mode of administration, side effects, etc.

### Conclusion

The development of a low literacy decision aid for RA medications in three languages was feasible using a collaborative process with patient, clinician and design input. Our decision aid, which is intended to be used in the context of an RA patient with moderate to high disease activity despite being on at least one DMARD, promoted a conversation and exchange of experience on the part of the clinician and values and preferences on the part of the patient. It is our expectation that the use of RA Choice in the clinical encounter will foster more patient-centered care and enhance shared decision-making for all RA patients.

### Practice implications

A clinical trial to test the final prototype of RA Choice is needed to determine its impact on patients and clinicians, its feasibility for use in usual care settings, and its impact on process and outcomes of care.

**Role of funding:** Funding for this project was from the Agency for Healthcare Research and Quality (R18 HS019209-01, PI Yelin). AHRQ had no role in study design; in collection, analysis and interpretation of data; in the writing of this manuscript; or in the decision to submit this paper for publication. Dr. Yelin, Ms. Trupin and Ms. Evans-Young also received funding from the NIH (NIAMS P60 AR053308).

### Competing interests

The authors declare that they have no competing interests.

### Authors' contributions

JLB conceived of the study, participated in its design and coordination and drafted the manuscript. CJK conducted the focus groups and interpretation of qualitative data used to inform the decision aid and helped draft the manuscript. GEY, LT, DS, and VMM participated in the design and coordination

of the study and helped draft the manuscript. JA contributed expertise in health literacy throughout the study and reviewed the manuscript. DR, MB, and TM participated in the design and creation of the decision aid and contributed to the drafting of the manuscript. EY conceived of the study, participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

### Acknowledgements

The authors would like to acknowledge all of the patients, patient families, clinicians, interpreters, and staff who dedicated their time to this project.

### Author details

<sup>1</sup>Department of Medicine, University of California, San Francisco, CA, USA. <sup>2</sup>Division of Hospital & Specialty Medicine, Portland Veterans Affairs Medical Center, 3710 SW US Veterans Hospital Road, Portland, OR 97239, USA. <sup>3</sup>Phillip R. Lee Institute for Health Policy Studies, San Francisco, CA, USA. <sup>4</sup>San Francisco, CA, USA. <sup>5</sup>Brooklyn, NY, USA. <sup>6</sup>Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, MN 55905, USA.

Received: 28 June 2014 Accepted: 3 November 2014

Published online: 25 November 2014

### References

- Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL: **British Society for Rheumatology Biologics R. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.** *Ann Rheum Dis* 2011, **70**(4):583–589. doi:10.1136/ard.2010.139774. PubMed PMID: 21330639; PubMed Central PMCID: PMC3048625.
- McBurney CA, Vina ER: **Racial and ethnic disparities in rheumatoid arthritis.** *Curr Rheumatol Rep* 2012, **14**(5):463–471. Epub 2012/07/10. doi:10.1007/s11926-012-0276-0. PubMed PMID: 22773376.
- Bruce B, Fries JF, Murtagh KN: **Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study.** *J Rheumatol* 2007, **34**(7):1475–1479. Epub 2007/06/07. PubMed PMID: 17552045.
- Barton JL, Trupin L, Schillinger D, Gansky SA, Tonner C, Margaretten M, Chernitskiy V, Graf J, Imboden J, Yelin E: **Racial and ethnic disparities in disease activity and function among persons with rheumatoid arthritis from university-affiliated clinics.** *Arthritis Care Res (Hoboken)* 2011, **63**(9):1238–1246. Epub 2011/06/15. doi:10.1002/acr.20525. PubMed PMID: 21671414; PubMed Central PMCID: PMC3169768.
- Caplan L, Wolfe F, Michaud K, Quinzanos I, Hirsh JM: **Strong association of health literacy with functional status among rheumatoid arthritis patients: a cross-sectional study.** *Arthritis Care Res (Hoboken)* 2014, **66**(4):508–514. Epub 2013/09/12. doi:10.1002/acr.22165. PubMed PMID: 24023051.
- Barton JL, Trupin L, Tonner C, Imboden J, Katz P, Schillinger D, Yelin E: **English language proficiency, health literacy, and trust in physician are associated with shared decision making in rheumatoid arthritis.** *J Rheumatol* 2014, **41**(7):7–1290. doi:10.3899/jrheum.131350. PubMed PMID: 24931952.
- de Wit MP, Smolen JS, Gossec L, van der Heijde DM: **Treating rheumatoid arthritis to target: the patient version of the international recommendations.** *Ann Rheum Dis* 2011, **70**(6):891–895. Epub 2011/04/12. doi:10.1136/ard.2010.146662. PubMed PMID: 21478190; PubMed Central PMCID: PMC3086033.
- Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D: **Treating rheumatoid arthritis to target: recommendations of an international task force.** *Ann Rheum Dis* 2010, **69**(4):631–637. Epub 2010/03/11. doi:10.1136/ard.2009.123919. PubMed PMID: 20215140; PubMed Central PMCID: PMC3015099.
- Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, et al: **EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.**

- Ann Rheum Dis* 2010, **69**(6):964–975. Epub 2010/05/07. doi:10.1136/ard.2009.126532. PubMed PMID: 20444750; PubMed Central PMCID: PMC2935329.
10. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgerief F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, et al: **EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.** *Ann Rheum Dis* 2014, **73**(3):492–509. Epub 2013/10/29. doi:10.1136/annrheumdis-2013-204573. PubMed PMID: 24161836; PubMed Central PMCID: PMC3933074.
  11. Breslin M, Mullan RJ, Montori VM: **The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetes.** *Patient Educ Couns* 2008, **73**(3):465–472. Epub 2008/09/06. doi:10.1016/j.pec.2008.07.024. PubMed PMID: 18771876.
  12. Mullan RJ, Montori VM, Shah ND, Christianson TJ, Bryant SC, Guyatt GH, Perestelo-Perez LI, Stroebel RJ, Yawn BP, Yapuncich V, Breslin MA, Pencille L, Smith SA: **The diabetes mellitus medication choice decision aid: a randomized trial.** *Arch Intern Med* 2009, **169**(17):1560–1568. Epub 2009/09/30. doi:10.1001/archinternmed.2009.293. PubMed PMID: 19786674.
  13. Jagosh J, Macaulay AC, Pluye P, Salsberg J, Bush PL, Henderson J, Sirett E, Wong G, Cargo M, Herbert CP, Seifer SD, Green LW, Greenhalgh T: **Uncovering the benefits of participatory research: implications of a realist review for health research and practice.** *Milbank Q* 2012, **90**(2):311–346. Epub 2012/06/20. doi:10.1111/j.1468-0009.2012.00665.x. PubMed PMID: 22709390; PubMed Central PMCID: PMC3460206.
  14. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkman ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG: **2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.** *Arthritis Care Res (Hoboken)* 2012, **64**(5):625–639. Epub 2012/04/05. doi:10.1002/acr.21641. PubMed PMID: 22473917.
  15. O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, Anis AH, Leatherman S, Keystone E: **Therapies for active rheumatoid arthritis after methotrexate failure.** *N Engl J Med* 2013, **369**(4):307–318. Epub 2013/06/13. doi:10.1056/NEJMoa1303006. PubMed PMID: 23755969.
  16. Charmaz K: **'Discovering' chronic illness: using grounded theory.** *Soc Sci Med* 1990, **30**(11):1161–1172. PubMed PMID: 2360052.
  17. Barton JL, Koenig CJ, Trupin L, Evans-Young G, Schillinger D, Yelin E: *Patient preferences and values associated with therapeutic options for rheumatoid arthritis: A qualitative study of patients and provider stakeholders across three languages.* St. Andrews, Scotland: International Conference on Communication in Healthcare; 2012.
  18. Seligman HK, Wallace AS, DeWalt DA, Schillinger D, Arnold CL, Shilliday BB, Delgadillo A, Bengal N, Davis TC: **Facilitating behavior change with low-literacy patient education materials.** *Am J Health Behav* 2007, **31**(Suppl 1):S69–S78. Epub 2007/10/20. doi:10.5555/ajhb.2007.31.supp.S69. PubMed PMID: 17931139.
  19. Bandura A: **Health promotion by social cognitive means.** *Health Educ Behav* 2004, **31**(2):143–164. Epub 2004/04/20. doi:10.1177/1090198104263660. PubMed PMID: 15090118.
  20. Choosing Medications for Rheumatoid Arthritis: *Clinician's Guide.* Rockville (MD): Comparative Effectiveness Review Summary Guides for Clinicians; 2007.
  21. Rheumatoid Arthritis Medicines: *A Guide for Adults.* Rockville (MD): Comparative Effectiveness Review Summary Guides for Consumers; 2005.
  22. Aaltonen KJ, Virkki LM, Malmivaara A, Kontinen YT, Nordstrom DC, Blom M: **Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.** *PLoS One* 2012, **7**(1):e30275. Epub 2012/01/25. doi:10.1371/journal.pone.0030275. PubMed PMID: 22272322; PubMed Central PMCID: PMC3260264.
  23. Katchamart W, Trudeau J, Phumethum V, Bombardier C: **Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis.** *Ann Rheum Dis* 2009, **68**(7):1105–1112. Epub 2008/12/05. doi:10.1136/ard.2008.099861. PubMed PMID: 19054823; PubMed Central PMCID: PMC2689526.
  24. Katchamart W, Trudeau J, Phumethum V, Bombardier C: **Methotrexate monotherapy versus methotrexate combination therapy with non-biological disease modifying anti-rheumatic drugs for rheumatoid arthritis.** *Cochrane Database Syst Rev* 2010, **4**:CD008495. Epub 2010/04/16. doi:10.1002/14651858.CD008495. PubMed PMID: 20393970.
  25. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, Bombardier C, Carmona L, van der Heijde D, Bijlsma JW, Boumpas DT, Canhao H, Edwards CJ, Hamuryudan V, Kvien TK, Leeb BF, Martin-Mola EM, Mielants H, Muller-Ladner U, Murphy G, Ostergaard M, Pereira IA, Ramos-Remus C, Valentini G, Zochling J, Dougados M: **Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative.** *Ann Rheum Dis* 2009, **68**(7):1086–1093. Epub 2008/11/27. doi:10.1136/ard.2008.094474. PubMed PMID: 19033291; PubMed Central PMCID: PMC2689523.
  26. LeBlanc A, Bodde AE, Branda ME, Yost KJ, Herrin J, Williams MD, Shah ND, Houten HV, Ruud KL, Pencille LJ, Montori VM: **Translating comparative effectiveness of depression medications into practice by comparing the depression medication choice decision aid to usual care: study protocol for a randomized controlled trial.** *Trials* 2013, **14**:127. Epub 2013/06/21. doi:10.1186/1745-6215-14-127. PubMed PMID: 23782672; PubMed Central PMCID: PMC3663744.
  27. Traynor K: **FDA approves tofacitinib for rheumatoid arthritis.** *American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists* 2012, **69**(24):2120. doi:10.2146/news120088. PubMed PMID: 23230026.
  28. Barton J, Koenig CJ, Trupin L, Evans-Young G, Schillinger D, Yelin E: *Patient preferences and values associated with therapeutic options for Rheumatoid Arthritis: A qualitative study of patients and provider stakeholders across three languages.* Denver CO: ACR Research Workshop; 2012. May 4-5, 2012.
  29. Constantinescu F, Goucher S, Weinstein A, Fraenkel L: **Racial disparities in treatment preferences for rheumatoid arthritis.** *Med Care* 2009, **47**(3):350–355. Epub 2009/01/24. doi:10.1097/MLR.0b013e31818af829. PubMed PMID: 19165120.
  30. Fraenkel L, Bogardus ST, Concato J, Felson DT, Wittink DR: **Patient preferences for treatment of rheumatoid arthritis.** *Ann Rheum Dis* 2004, **63**(11):1372–1378. Epub 2004/03/17. doi:10.1136/ard.2003.019422. PubMed PMID: 15020312; PubMed Central PMCID: PMC1754807.
  31. Pasma A, van't Spijker A, Hazes JM, Busschbach JJ, Luime JJ: **Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review.** *Semin Arthritis Rheum* 2013, **43**(1):18–28. Epub 2013/01/29. doi:10.1016/j.semarthrit.2012.12.001. PubMed PMID: 23352247.
  32. Sanderson T, Calnan M, Morris M, Richards P, Hewlett S: **The impact of patient-perceived restricted access to anti-TNF therapy for rheumatoid arthritis: a qualitative study.** *Musculoskeletal Care* 2009, **7**(3):194–209. Epub 2009/01/08. doi:10.1002/msc.149. PubMed PMID: 19127529; PubMed Central PMCID: PMC2886965.
  33. Barton JL: **Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy.** *Patient Prefer Adherence* 2009, **3**:335–344. Epub 2009/12/18. PubMed PMID: 20016797; PubMed Central PMCID: PMC2792871.
  34. Fagerlin A, Zikmund-Fisher BJ, Ubel PA: **Helping patients decide: ten steps to better risk communication.** *J Natl Cancer Inst* 2011, **103**(19):1436–1443. Epub 2011/09/21. doi:10.1093/jnci/djr318. PubMed PMID: 21931068; PubMed Central PMCID: PMC3218625.
  35. Chung CP, Thompson JL, Koch GG, Amara I, Strand V, Pincus T: **Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities.** *Ann Rheum Dis* 2006, **65**(12):1602–1607. Epub 2006/03/01. doi:10.1136/ard.2005.048975. PubMed PMID: 16504992; PubMed Central PMCID: PMC1798472.
  36. Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, Gossec L, Landewe R, Smolen JS, Buch MH: **Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.** *Ann Rheum Dis* 2014,

- 73(3):516–528. Epub 2014/01/09. doi:10.1136/annrheumdis-2013-204577. PubMed PMID: 24399231.
37. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL Jr, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS: **A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.** *Arthritis Rheum* 2012, **64(9)**:2824–2835. Epub 2012/04/18. doi:10.1002/art.34498. PubMed PMID: 22508468; PubMed Central PMCID: PMC4036119.
38. DeWalt DA, Davis TC, Wallace AS, Seligman HK, Bryant-Shilliday B, Arnold CL, Freburger J, Schillinger D: **Goal setting in diabetes self-management: taking the baby steps to success.** *Patient Educ Couns* 2009, **77(2)**:218–223. Epub 2009/04/11. doi:10.1016/j.pec.2009.03.012. PubMed PMID: 19359123.
39. Heisler M, Vijan S, Anderson RM, Ubel PA, Bernstein SJ, Hofer TP: **When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make?** *J Gen Intern Med* 2003, **18(11)**:893–902. Epub 2003/12/23. PubMed PMID: 14687274; PubMed Central PMCID: PMC1494939.
40. Maneesriwongul W, Dixon JK: **Instrument translation process: a methods review.** *J Adv Nurs* 2004, **48(2)**:175–186. Epub 2004/09/17. doi:10.1111/j.1365-2648.2004.03185.x. PubMed PMID: 15369498.
41. Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB, Holmes-Rovner M, Llewellyn-Thomas H, Lyddiatt A, Thomson R, Trevena L, Wu JH: **Decision aids for people facing health treatment or screening decisions.** *Cochrane Database Syst Rev* 2014, **1**:CD001431. Epub 2014/01/29. doi: 10.1002/14651858.CD001431.pub4. PubMed PMID: 24470076.
42. Fraenkel L, Peters E, Charpentier P, Olsen B, Errante L, Schoen RT, Reyna V: **Decision tool to improve the quality of care in rheumatoid arthritis.** *Arthritis Care Res (Hoboken)* 2012, **64(7)**:977–985. Epub 2012/03/07. doi:10.1002/acr.21657. PubMed PMID: 22392766; PubMed Central PMCID: PMC3375390.
43. Martin RW, Brower ME, Gerald A, Gallagher PJ, Tellinghuisen DJ: **An experimental evaluation of patient decision aid design to communicate the effects of medications on the rate of progression of structural joint damage in rheumatoid arthritis.** *Patient Educ Couns* 2012, **86(3)**:329–334. Epub 2011/07/15. doi:10.1016/j.pec.2011.06.001. PubMed PMID: 21752570.
44. Li LC, Adam PM, Backman CL, Lineker S, Jones CA, Lacaille D, Townsend AF, Yacyszyn E, Yousefi C, Tugwell P, Leese J, Stacey D. A proof-of-concept study of ANSWER, a web-based methotrexate decision aid for patients with rheumatoid arthritis. *Arthritis care & research*. 2014. doi:10.1002/acr.22319. PubMed PMID: 24623617
45. Coulter A, Stilwell D, Kryworuchko J, Mullen PD, Ng CJ, van der Weijden T: **A systematic development process for patient decision aids.** *BMC Med Inform Decis Mak* 2013, **13(Suppl 2)**:S2.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

